Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia. [electronic resource]
Producer: 19970825Description: 1226-32 p. digitalISSN:- 0006-4971
- Adolescent
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Asparaginase -- administration & dosage
- Biomarkers, Tumor -- analysis
- Blotting, Southern -- methods
- Bone Marrow -- pathology
- Child
- Child, Preschool
- Cohort Studies
- Cyclophosphamide -- administration & dosage
- Cytarabine -- administration & dosage
- DNA, Neoplasm -- analysis
- Daunorubicin -- administration & dosage
- Disease-Free Survival
- Evaluation Studies as Topic
- Female
- Fluorometry
- Gene Rearrangement, delta-Chain T-Cell Antigen Receptor
- Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor
- Humans
- Immunophenotyping
- Infant
- Italy -- epidemiology
- Leucovorin -- administration & dosage
- Leukemia-Lymphoma, Adult T-Cell -- drug therapy
- Male
- Mercaptopurine -- administration & dosage
- Methotrexate -- administration & dosage
- Neoplasm, Residual
- Neoplastic Stem Cells -- chemistry
- Nucleic Acid Hybridization -- methods
- Polymerase Chain Reaction -- methods
- Prednisone -- administration & dosage
- Prognosis
- Prospective Studies
- Receptors, Antigen, T-Cell, gamma-delta -- analysis
- Remission Induction
- Sensitivity and Specificity
- Treatment Outcome
- Vincristine -- administration & dosage
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.